Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_000314.8 | MANE Select | 8515 nt | 846–2057 |
| NM_000314.7 | RefSeq Select | 8514 nt | 845–2056 |
| NM_000314.5 | Alternative | 8719 nt | 1032–2243 |
| NM_000314.4 | Alternative | 5572 nt | 1032–2243 |
| NM_000314.3 | Alternative | 3416 nt | 1032–2243 |
| NM_000314.6 | Alternative | 8718 nt | 1032–2243 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenThe c.493-1G>A intronic pathogenic mutation results from a G to A substitution one nucleotide upstream from coding exon 6 of the PTEN gene. This alteration has been identified in individuals with PTEN-related disease (Ambry internal data; De Rubeis S et al. Nature, 2014 Nov;515:209-15; Wang T et al. Nat Commun, 2016 11;7:13316; Kosmicki JA et al. Nat. Genet., 2017 Apr;49:504-510). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and will result in the creation or strengthening of a novel splice acceptor site; however, direct evidence is insufficient at this time (Ambry internal data). In addition to the clinical data, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 189409). Disruption of this splice site has been observed in individuals with PTEN hamartoma tumor syndrome (PMID: 17526801, 28677221). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 5 of the PTEN gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PTEN are known to be pathogenic (PMID: 9467011, 21194675).
"This variant has been reported in ClinVar as Pathogenic (3 clinical laboratories)."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.99 | 1 bp |
| Donor Loss (DL) | 0.17 | 142 bp |
| Acceptor Gain (AG) | 0.76 | 2 bp |
| Donor Gain (DG) | 0.0 | 2 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PVS1 (Very Strong)
According to VCEP guidelines, the rule for PVS1 is: 'Null Variant (nonsense, fs, start codon, splicing +1/2, startgain, single or multi-exon deletion) in a gene where LOF is a known mechanism of disease' at Very Strong strength. The evidence for this variant shows a canonical splice acceptor site mutation (c.493-1G>A) predicted to abolish normal splicing, not in the last exon. Therefore, this criterion is applied at Very Strong strength because a +/−1 canonical splice variant is predicted to result in loss of function in PTEN.
PS1 (Not Applied)
According to VCEP guidelines, PS1 requires a different variant at the same nucleotide as a known pathogenic splicing variant with equal or greater in silico impact. There is no previously established pathogenic variant at c.493-1. Therefore, PS1 is not applied.
PS2 (Not Applied)
According to VCEP guidelines, PS2 requires de novo observation(s) with appropriate confirmation. No de novo data are provided for this variant. Therefore, PS2 is not applied.
PS3 (Not Applied)
According to PTEN pre-processing, the variant was not found in the functional assay dataset (Table S2-Table 1.csv); no well-established in vitro or in vivo functional studies are available. Therefore, PS3 is not applied.
PS4 (Not Applied)
According to VCEP guidelines, PS4 requires case-control data or proband specificity scores. No prevalence or proband specificity data are provided. Therefore, PS4 is not applied.
PM1 (Not Applied)
According to VCEP guidelines, PM1 applies to variants in critical catalytic motifs (residues 90-94, 123-130, 166-168). This splice variant is outside those regions. Therefore, PM1 is not applied.
PM2 (Supporting)
According to VCEP guidelines, PM2 is: 'Absent in population databases present at <0.001% allele frequency in gnomAD'. The evidence shows the variant is absent from gnomAD. Therefore, PM2 is applied at Supporting strength because the allele is not observed in large population datasets.
PM3 (Not Applied)
According to standard ACMG guidelines, PM3 applies to recessive inheritance with variants in trans. PTEN is associated with autosomal dominant disease, and no trans observations are reported. Therefore, PM3 is not applied.
PM4 (Not Applied)
According to standard ACMG guidelines, PM4 applies to in-frame indels or stop-loss variants. This is a splice-site variant, not an in-frame indel. Therefore, PM4 is not applied.
PM5 (Not Applied)
According to VCEP guidelines, PM5 applies to missense changes at residues with known pathogenic missense variants. This is a splice acceptor variant, not missense. Therefore, PM5 is not applied.
PM6 (Not Applied)
According to VCEP guidelines, PM6 requires assumed de novo occurrence without confirmation. No presumed de novo data are available. Therefore, PM6 is not applied.
PP1 (Not Applied)
According to VCEP guidelines, PP1 requires co-segregation in multiple affected family members. No segregation data are provided. Therefore, PP1 is not applied.
PP2 (Not Applied)
According to standard ACMG guidelines, PP2 applies to missense variants in genes with low benign missense variation. This is a splice variant, not missense. Therefore, PP2 is not applied.
PP3 (Supporting)
According to VCEP guidelines, PP3 for splicing variants is: 'Concordance of SpliceAI and VarSeak predictions.' SpliceAI predicts high impact on splicing (score 0.99). Therefore, PP3 is applied at Supporting strength because computational evidence supports a deleterious splicing effect.
PP4 (Not Applied)
According to standard ACMG guidelines, PP4 requires a specific phenotype with a single genetic etiology. No phenotype information is provided. Therefore, PP4 is not applied.
PP5 (Supporting)
According to standard ACMG guidelines, PP5 is: 'Reputable source reports variant as pathogenic without accessible evidence.' ClinVar lists this variant as Pathogenic from three clinical laboratories. Therefore, PP5 is applied at Supporting strength.
BA1 (Not Applied)
According to VCEP guidelines, BA1 applies when allele frequency >0.056%. The variant is absent from population databases. Therefore, BA1 is not applied.
BS1 (Not Applied)
According to VCEP guidelines, BS1 applies for allele frequency between 0.0043% and 0.056%. The variant is absent. Therefore, BS1 is not applied.
BS2 (Not Applied)
According to VCEP guidelines, BS2 requires homozygous observations in unaffected individuals. No such data exist. Therefore, BS2 is not applied.
BS3 (Not Applied)
According to VCEP guidelines, BS3 requires functional studies showing no damaging effect. No functional data are available. Therefore, BS3 is not applied.
BS4 (Not Applied)
According to VCEP guidelines, BS4 requires lack of segregation in affected families. No segregation data are provided. Therefore, BS4 is not applied.
BP1 (Not Applied)
According to standard ACMG guidelines, BP1 applies to missense variants in genes where only LOF is pathogenic. This is a splice variant causing LOF. Therefore, BP1 is not applied.
BP2 (Not Applied)
According to VCEP guidelines, BP2 requires observations in trans or cis with other PTEN variants. No such data are reported. Therefore, BP2 is not applied.
BP3 (Not Applied)
According to standard ACMG guidelines, BP3 applies to in-frame indels in repeat regions. Not applicable to this splice variant. Therefore, BP3 is not applied.
BP4 (Not Applied)
According to VCEP guidelines, BP4 requires computational evidence of no impact. Computational predictions are discordant but SpliceAI indicates impact. Therefore, BP4 is not applied.
BP5 (Not Applied)
According to VCEP guidelines, BP5 applies when an alternate molecular basis is found. No alternate etiology is reported. Therefore, BP5 is not applied.
BP6 (Not Applied)
According to standard ACMG guidelines, BP6 applies to reputable sources reporting a variant as benign without evidence. ClinVar reports this variant as pathogenic, not benign. Therefore, BP6 is not applied.
BP7 (Not Applied)
According to VCEP guidelines, BP7 applies to synonymous or deep intronic variants predicted to have no impact. This is a canonical splice site variant. Therefore, BP7 is not applied.